Meeting
2015 ASCO Annual Meeting
Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer.
Authors
Yelena Yuriy Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Yuriy Janjigian , Geoffrey Yuyat Ku , Joanne F. Chou , Marinela Capanu , Marisa Siebel , Sree Bhavani Chalasani , Michelle S. Boyar , Zoe Goldberg , Avni Mukund Desai , David Paul Kelsen , Tooba Imtiaz , David H. Ilson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01913639
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4053)
DOI
10.1200/jco.2015.33.15_suppl.4053
Abstract #
4053
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
SBRT with ipilimumab and nivolumab to metastatic MSS colorectal and pancreatic cancer: A pooled analysis of four prospective phase II trials.
First Author: Hannah Johnson Roberts
First Author: Sandra Algaze
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.
First Author: Celine Yeh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Genomic characterization of unresectable/recurrent early-onset gastric cancer by comprehensive genomic profiling tests.
First Author: Kunihito Matsuguma